Litcius/Paper detail

The Finding of N-Nitrosodimethylamine in Common Medicines

Richard H. Adamson, Bruce A. Chabner

2020The Oncologist23 citationsDOIOpen Access PDF

Abstract

The FDA has ordered the withdrawal of all ranitidine products from the marketplace based on recent findings of increased and unacceptable levels of N-nitrosodimethylamine (NDMA). This commentary reviews the sources and properties of NDMA, assesses the dangers it poses, and suggests measures to mitigate contamination.

Topics & Concepts

N-NitrosodimethylamineMedicineRanitidineIntensive care medicineEnvironmental healthPharmacologyCarcinogenGeneticsBiologyWater Treatment and DisinfectionPediatric health and respiratory diseases